NovaBridge Biosciences (FRA:0VY)

Germany flag Germany · Delayed Price · Currency is EUR
3.300
+0.080 (2.48%)
Last updated: Jan 27, 2026, 8:04 AM CET
236.73%
Market Cap321.20M +272.3%
Revenue (ttm)n/a
Net Income-22.44M
EPS-0.26
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume548
Open3.300
Previous Close3.220
Day's Range3.300 - 3.300
52-Week Range0.555 - 5.600
Betan/a
RSI42.96
Earnings DateApr 1, 2026

About NovaBridge Biosciences

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, imp... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2014
Employees 32
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0VY
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements